- Home
- INTS vs TRAW Comparison
INTS vs TRAW Comparison
Compare INTS & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- TRAW
- Stock Information
- Founded
- INTS 2012
- TRAW 1998
- Country
- INTS United States
- TRAW United States
- Employees
- INTS N/A
- TRAW N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- TRAW
- Sector
- INTS Health Care
- TRAW
- Exchange
- INTS Nasdaq
- TRAW NYSE
- Market Cap
- INTS 8.4M
- TRAW 8.6M
- IPO Year
- INTS 2023
- TRAW 2013
- Fundamental
- Price
- INTS $0.28
- TRAW $1.54
- Analyst Decision
- INTS Strong Buy
- TRAW
- Analyst Count
- INTS 2
- TRAW 0
- Target Price
- INTS $6.75
- TRAW N/A
- AVG Volume (30 Days)
- INTS 5.7M
- TRAW 73.0K
- Earning Date
- INTS 08-11-2025
- TRAW 08-14-2025
- Dividend Yield
- INTS N/A
- TRAW N/A
- EPS Growth
- INTS N/A
- TRAW N/A
- EPS
- INTS N/A
- TRAW N/A
- Revenue
- INTS N/A
- TRAW $227,000.00
- Revenue This Year
- INTS N/A
- TRAW $3.81
- Revenue Next Year
- INTS N/A
- TRAW $30.43
- P/E Ratio
- INTS N/A
- TRAW N/A
- Revenue Growth
- INTS N/A
- TRAW 0.44
- 52 Week Low
- INTS $0.26
- TRAW $0.97
- 52 Week High
- INTS $4.94
- TRAW $19.44
- Technical
- Relative Strength Index (RSI)
- INTS 35.87
- TRAW 47.86
- Support Level
- INTS $0.32
- TRAW $1.50
- Resistance Level
- INTS $0.36
- TRAW $1.64
- Average True Range (ATR)
- INTS 0.03
- TRAW 0.09
- MACD
- INTS 0.00
- TRAW -0.01
- Stochastic Oscillator
- INTS 1.88
- TRAW 26.92
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.